|Moderated By: RMP -- (Not Moderated) -- Started: 1/4/2000 9:04:00 PM Revision History|
"TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellular and synthetic vectors -. TRANSGENE currently has four Phase II studies ongoing targeting four different types of cancer. TRANSGENE has signed two significant partnerships, with Schering-Plough Inc. and with Human Genome Sciences Inc. (HGSI). Based in Strasbourg, France with US offices in Boston, Massachusetts, TRANSGENE is listed on the Nasdaq and the Nouveau Marché."
The above information comes from Transgene's home page. This is a stock I've been following for quite some time, primarily because of its relationship with Human Genome Sciences (HGSI). However, while HGSI has skyrocketed (prior to today's biotech selloff), Transgene has been stagnant with generally light daily volume. Is it possible this is the sleeper among biotechs?
Copyright © 1995-2013 Knight Sac Media. All rights reserved.